冬虫夏草中虫草多糖的药理研究进展  

Progress in Pharmacological Research of Cordyceps Polysaccharides from Ophiacordyceps sinensis

作　　者：胡贤达 周菲[1] 黄雪[2] 岳颖[1] 黄福开[1] 

机构地区：[1]中国藏学研究中心北京藏医院,北京100029 [2]南方医科大学肿瘤研究所,广州510515

出　　处：《中国实验方剂学杂志》2016年第6期224-229,共6页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：国家重大财政专项(1981320400011);北京市中医药科技项目(JJ2013-52)

摘　　要：冬虫夏草(Ophiacordyceps sinensis,CS)是一种有至少五百年应用历史的传统名贵药物。虫草多糖(O.sinensis polysaccharides,CSP)作为CS中主要生物活性成分之一,具有广泛的药理作用。CSP的组成十分复杂,其单一组分的分离纯化及分析鉴定,对于研究CSP及CS复杂的药理作用机制具有重要的意义。近年来,关于CSP尤其是其单一组分的分离及药理机制研究发展较快,发现CSP具有免疫调节、抗肿瘤、抗氧化、降血糖及血脂等药理活性,具有广阔的应用前景。本文总结归纳了其近期主要的药理研究进展,并对其未来的开发潜力及发展方向进行了展望。Ophiocordyceps sinensis（ CS） has been used medicinally for at least 500 years. O. sinensis polysaccharides（ CSP）,as one of the major bioactive constituents of CS,have exhibited extensive therapeutic effect. Analysis shows that CSPs contain complex compositions, so the isolation, purification, analysis and identification of individual compositions are significant for research on complex pharmacological mechanism of CSP and CS. In recent years,many studies on CSPs,especially the isolation and pharmacological mechanism research of individual compositions have been carried out,indicating that CSPs have varied pharmacological effects such as immune-modulatory,anti-cancer,anti-oxidation,anti-hyperglycemia and anti-hyperlipidemia,with broad application prospects. The current progress on pharmacological research and future prospects are reviewed in this paper.

关 键 词：冬虫夏草 虫草多糖 药理作用 分子机制 

分 类 号：R285[医药卫生—中药学]